文献速递儿童呼吸儿童感染

马拉维2至59月龄儿童非严重呼吸急促肺炎的安慰剂与阿莫西林对比:双盲随机临床非劣效性试验

Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial.
PubMed 文献 · JAMA Pediatr · 2019-01-01

该双盲随机非劣效性试验在马拉维筛查1343例HIV未感染2至59月龄非严重呼吸急促肺炎患儿,随机1126例接受3天阿莫西林或安慰剂治疗。因阿莫西林组第4天治疗失败率4.0%显著低于安慰剂组7.0%,数据安全监察委员会提前终止试验;第14天治疗失败或复发两组无显著差异,无死亡。

要点

  • 在马拉维HIV未感染2至59月龄患儿中,安慰剂治疗非严重呼吸急促肺炎显著劣于阿莫西林。
  • 阿莫西林组第4天治疗失败率4.0%,安慰剂组7.0%,调整相对风险1.78(95%CI 1.07%-2.97%)。
  • 第14天治疗失败或复发两组无显著差异,需阿莫西林治疗1例获益的患儿数为33。

核心结论

  • 在马拉维疟疾流行区HIV未感染2至59月龄儿童中,安慰剂治疗非严重呼吸急促肺炎显著劣于3天阿莫西林治疗。
  • 尽管安慰剂组第4天约93%患儿无治疗失败,且第14天治疗失败或复发两组无显著差异,但主要终点支持阿莫西林优于安慰剂。

研究设计与样本

  • 双盲、2臂、随机临床非劣效性试验,随访14天,在马拉维利隆圭医院门诊筛查1343例HIV未感染2至59月龄非严重呼吸急促肺炎患儿。
  • 共1126例患儿随机接受安慰剂或阿莫西林分散片每日两次、连续3天治疗,主要分析基于意向性治疗原则。

主要发现

  • 阿莫西林组第4天治疗失败率4.0%(22/552),安慰剂组7.0%(38/543),调整相对风险1.78(95%CI 1.07%-2.97%),调整绝对差3.0%(95%CI 0.4%-5.7%)。
  • 第14天治疗失败或复发:阿莫西林组10.1%(56/552),安慰剂组11.8%(64/543),相对风险1.16(95%CI 0.83%-1.63%),绝对差1.6%(95%CI -2.1%至5.4%)。
  • 研究无死亡病例,数据安全监察委员会因阿莫西林组治疗失败率显著更低而提前终止试验。

关键数值与推荐

  • 主要终点为第4天治疗失败比例,相对非劣效性界值为阿莫西林组失败率的1.5倍。
  • 需阿莫西林治疗1例获益的患儿数为33。

临床怎么用

  • 在类似马拉维的低资源非洲疟疾流行区,HIV未感染2至59月龄非严重呼吸急促肺炎患儿不应使用安慰剂替代阿莫西林。
  • 临床决策需结合当地资源与患儿具体情况,该试验支持3天阿莫西林治疗在该人群中的获益。

局限性

  • 试验因中期分析提前终止,可能影响结果稳定性。
  • 研究对象为HIV未感染儿童且位于马拉维疟疾流行区,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pneumonia is the leading infectious killer of children. Rigorous evidence supporting antibiotic treatment of children with nonsevere fast-breathing pneumonia in low-resource African settings is lacking. OBJECTIVE: To assess whether treatment with placebo for nonsevere fast-breathing pneumonia is substantively less effective than 3 days of treatment with amoxicillin. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, 2-arm, randomized clinical noninferiority trial with follow-up of 14 days screened 1343 HIV-uninfected children aged 2 to 59 months with nonsevere fast-breathing pneumonia at outpatient departments of hospitals in Lilongwe, Malawi, Africa, between June 2016 and June 2017. INTERVENTIONS: Placebo or amoxicillin dispersible tablets administered twice daily for 3 days. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of children failing treatment by day 4 with a relative noninferiority margin of 1.5 times the failure rate in the amoxicillin group. Primary analyses were performed based on the intention-to-treat principle. Planned secondary analyses included treatment failure or relapse by day 14. RESULTS: In total, 1126 children were randomized to 3 days of amoxicillin (n = 564) or placebo (n = 562) therapy. Baseline demographic and clinical characteristics were similar between the groups. For the entire study population, the mean (SD) age was 21.3 (15.1) months, and 601 (53.4%) were female. After an interim analysis, the data safety monitoring board stopped the study because children receiving amoxicillin had a 4.0% (22 of 552 with outcome data) treatment failure rate by day 4, whereas children receiving placebo had a 7.0% (38 of 543) treatment failure rate (adjusted relative risk, 1.78; 95% CI, 1.07%-2.97%; adjusted absolute difference, 3.0%; 95% CI, 0.4%-5.7%). Among children with known day 14 outcomes, 56 of 552 (10.1%) receiving amoxicillin and 64 of 543 (11.8%) receiving placebo had either treatment failure by day 4 or relapse by day 14 (relative risk, 1.16; 95% CI, 0.83%-1.63%; absolute difference, 1.6%; 95% CI, -2.1% to 5.4%). There were no deaths. CONCLUSIONS AND RELEVANCE: In HIV-uninfected children aged 2 to 59 months in a malaria-endemic region of Malawi, placebo treatment of nonsevere fast-breathing pneumonia was significantly inferior to treatment with amoxicillin. However, by day 4, approximately 93% of children receiving placebo were without treatment failure, and there was no significant difference between groups in treatment failure or relapse by day 14. The number of children with nonsevere fast-breathing pneumonia that needed amoxicillin treatment for 1 child to benefit was 33. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02760420.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Ginsburg AS, Mvalo T, Nkwopara E, et al. Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial. JAMA Pediatr. 2019. PMID: 30419120. doi:10.1001/jamapediatrics.2018.3407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。